Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice.

A consortium led by Vanderbilt University Medical Center (VUMC) researchers has received funding as it makes plans for a multicenter trial that could determine whether deep brain stimulation (DBS) slows the progression of Parkinson’s disease in early-stage patients.

Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.

People with Alzheimer’s disease don’t perceive pain as readily as healthy older adults, and this may lead to delays and underreporting of pain. This alteration in pain detection may be one reason that people with Alzheimer’s disease and pain tend to be undermedicated and suffer unnecessarily, a trans-institutional group of Vanderbilt researchers reported recently in BMC Medicine.

A genetic risk factor for Alzheimer’s disease in later life appears to benefit younger adults as they age.

Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment.

A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation.